内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetes Care：HDL-C和HDL-C/apoA-I可预测2型糖尿病的血糖长期进展

2014-06-03 CMT 中国医学论坛报糖尿病手机报

HDL-C2型糖尿病血糖
关注

一项多国联合研究显示，低高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A-I(apoA-I)以及HDL-C/apoA-I与胰岛素抵抗相关，但是与糖化血红蛋白(HbA1C)无关。论文5月21日在线发表于《糖尿病护理》(Diabetes Care)杂志。 研究者纳入9795例2型糖尿病患者，计算基线空腹HDL-C、apoA-I、HDL-C/apoA-I与HbA1C的相关性，在仅使用外源性胰岛素者中，则计

一项多国联合研究显示，低高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A-I(apoA-I)以及HDL-C/apoA-I与胰岛素抵抗相关，但是与糖化血红蛋白(HbA1C)无关。论文5月21日在线发表于《糖尿病护理》(Diabetes Care)杂志。

研究者纳入9795例2型糖尿病患者，计算基线空腹HDL-C、apoA-I、HDL-C/apoA-I与HbA1C的相关性，在仅使用外源性胰岛素者中，则计算上述指标与估计β细胞功能及胰岛素的相关性。

结果显示，基线HDL-C、apoA-I、HDL-C/apoA-I与胰岛素抵抗反相关(P均<0.001)，但与HbA1C无关(P均>0.05)。ApoA-I还与β细胞功能反相关。此外，基线HDL-C水平较低和HDL-C/apoA-I较小可预测更大量、更早地使用口服降糖药和胰岛素(P均<0.01)。

原始出处：


Waldman B1, Jenkins AJ2, Davis TM3, Taskinen MR4, Scott R5, O'Connell RL2, Gebski VJ2, Ng MK6, Keech AC7; on behalf on behalf of the FIELD Study investigators.HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes.Diabetes Care. 2014 May 7. pii: DC_132738. [Epub ahead of print]
 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-06-16 木头人513

    #Diabetes#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2015-04-11 x35042875

    国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-07-01 海豹

    #apoA-I#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-07-11 ms9608593228839890

    #DIA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-12-03 智智灵药

    #BET#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-07-24 qingfengqishi5

    HDL-C/apoA-I 有新意哦！

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-06-10 chen111111

    有新意，提供一些思路

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-06-05 ZGMFX24A

    #HDL#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1901216, encodeId=3fee19012168c, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jun 16 08:30:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20811, encodeId=870120811ae, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:47:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779993, encodeId=b05b1e799938a, content=<a href='/topic/show?id=51382654b6' target=_blank style='color:#2F92EE;'>#apoA-I#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2654, encryptionId=51382654b6, topicName=apoA-I)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Tue Jul 01 14:30:00 CST 2014, time=2014-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636882, encodeId=62f3163688222, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 11 14:30:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759456, encodeId=bfa41e59456a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 03 02:30:00 CST 2014, time=2014-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10595, encodeId=cdfe1059573, content=HDL-C/apoA-I 有新意哦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Jul 24 00:35:00 CST 2014, time=2014-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9776, encodeId=07f99e7606, content=有新意，提供一些思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Tue Jun 10 17:22:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316407, encodeId=2c71131640ee6, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480814, encodeId=dc9014808144a, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Thu Jun 05 09:30:00 CST 2014, time=2014-06-05, status=1, ipAttribution=)]
    2014-06-05 ms920641618706883

    #HDL-C#

    0

相关资讯

JACC：HDL-C在正常LDL-C水平下仍为不良心血管事件重要预测因子

研究要点：一些分析认为，即时LDL-C水平正常，HDL-C水平仍可预测不良心血管事件；但是也有分析认为，如果使用降脂治疗尤其是使用他汀类药物将LDL-C水平降至很低水平时，HDL-C与不良心血管事件之间可能并无相关性。研究人员进行本次分析，旨在评估对于已接受最佳治疗措施的稳定性缺血性心血管疾病患者(SIHD)患者而言，HDL-C水平对心血管疾病风险的独立影响。本项研究结果显示，即使LDL-C水平在

Diabetes Care：HDL-C水平低的糖尿病患者要尽早药物降糖

为期5年的FIELD（非诺贝特干预降低糖尿病事件研究）研究显示，在2型糖尿病患者中，基线高密度脂蛋白胆固醇（HDL-C）、载脂蛋白A-I（apoA-I）和HDL-C/apoA-I比值等与胰岛素抵抗指数负相关，但与HbA1c水平无关。ApoA-I水平还与β细胞功能负相关。研究者发现，HDL-C水平和HDL-C/apoA-I比值较低预示着患者需要尽早应用药物进行降糖治疗。（Diabetes Care.

ASH 2014：探寻高血压患者中脉搏波速度与HDL-C的相关性

既往研究表明，脉搏波速度（PWV）所测得的动脉僵硬度增加是心血管疾病的独立预测因素，高密度脂蛋白胆固醇（HDL-C）水平降低可增加冠状动脉疾病发生风险。中国一项研究旨在探讨高血压患者中PWV与HDL-C的相关性。 研究者Hongyu Wang等人共计入选542例受试者（男/女：336/206，平均年龄为50.17±12.32岁），将其分为对照组（n=402，男/女：234/168，平均年龄为48